---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016868"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:00:38.461538+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q2 net loss $27M; NKX101 AML 60% CR, NKX019 NHL 50% CR

## Summary
- Q2 2022 net loss $27.0M ($0.61/share); cash & investments $415.0M, sufficient into 2025.
- NKX101 Phase 1: 3/5 AML patients at higher dose achieved CR (60%); 2 of 3 MRD-negative.
- NKX019 Phase 1: 3/6 NHL patients at higher dose achieved CR (50%); included DLBCL and MCL.
- Raised ~$215.6M net from public offering in April 2022; lease amendments add $15M tenant improvements.
- Promoted leaders: Dr. Brandenberger to CTO, Yvonne Li to CAO, Dr. Shook to VP Clinical Dev.

## SEC filing metadata
- accession: 0000950170-22-016868
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022016868/0000950170-22-016868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022016868/nktx-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016868
- JSON: https://secwatch.observer/filing/0000950170-22-016868.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.